The diagnostic value of serum IGF-II in combination with IGF-I and IGFBP-3 in Silver-Russell syndrome

Gerhard Binder1, Thomas Eggermann2, Karin Weber1, Roland Schweizer1
1University Children’s Hospital, Pediatric Endocrinology, Tuebingen, Germany
2Institute of Human Genetics, RWTH Aachen, Aachen, Germany

Introduction
Recently we described a multigenerational family with severe intrauterine and postnatal growth failure as well as signs of Silver-Russell syndrome (SRS) who carried a heterozygote nonsense mutation of IGF2 (1). The patients had low IGF-II serum levels, but normal IGF-I levels. Here, we aimed to estimate the diagnostic value of IGF-II in combination with IGF-I and IGFBP-3 in the assessment of children with SRS.

Individuals
We collected the data from 52 children with SRS (23 girls) with complete genetic and endocrine analysis, and 113 children with non-syndromic SGA short stature, seen during the last 20 years at our centre. The SRS children were 4.7 ± 2.1 y of age. A cohort of 113 SGA children aged 5.7 ± 1.8 y served as comparison. All patients were prepubertal and GH treatment naive when tested.

Table 1 The SRS patients fulfilled at least 4 of the following 6 criteria (NH-score):

- SGA at birth
- failure to thrive in infancy or BMI < -2 SDS
- short stature
- relative macrocephaly
- prominent forehead
- body asymmetry

Methods
IGF-II, IGF-I and IGFBP-3 were measured by the same in-house RIAs during the full study period (2-3). Hormone SDS values are based on a reference cohort of healthy German and Danish children.

Conclusions
The molecular diagnosis in SRS can be predicted by measuring serum IGF-II in combination with IGF-I and IGFBP-3 as well as by calculating the IGF-II to IGF-I concentration ratio. The flow chart illustrates the predictive power of this approach:

![Flow chart showing the predictive power of IGF-II to IGF-I ratio for SRS diagnosis.]

Disclosure:
the authors have nothing to disclose

Correspondence:
gerhard.binder@med.uni-tuebingen.de

References